ECOG-ACRIN and PrECOG announce multiple presentations at ASH 2024
Researchers with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and PrECOG, LLC, will present a variety of abstracts that aim to improve treatments for patients with lymphomas and acute leukemias at the 66th American Society of Hematology (ASH) Meeting & Exposition. The meeting is set to occur in San Diego, California, and virtually December 7 - 10, 2024.
Promising results from a phase 2 study (PrE0905) in patients with acute myeloid leukemia and new data from the practice-changing E1910 phase 3 trial are among the highlights. Results from the E1910 trial led to an FDA approval in June 2024 after it found that adding the immunotherapy drug blinatumomab to standard front-line consolidation chemotherapy keeps most patients with B-cell acute lymphoblastic leukemia in remission and improves their survival.
Details for the presentations are below, listed by type and date. Times are shown in Pacific Time.
New Data from the Practice-Changing E1910 Trial by ECOG-ACRIN
-
Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial
Presenter: Nikolai A. Podoltsev, MD, PhD (Yale University)
Poster Abstract 4211 in Session 613
Date and Time: Monday, December 9, 2024, 6:00 - 8:00 PM
Location: San Diego Convention Center, Halls G-H - Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial
Presenter: Michaela Liedtke, MD (Stanford University)
Oral Abstract 779 in Session 732
Date and Time: Monday, December 9, 10:30 AM - 12:00 PM
Presentation Time: 11:30 AM
Location: San Diego Convention Center, Room 6A - EBF1 Activity Controls Leukemia Sensitivity to Inotuzumab Ozogamicin
Presenter: Carolin S. Escherich, MD (St. Jude Children’s Research Hospital)
Oral Abstract 830 in Session 605
Date and Time: Monday, December 9, 2:45 - 4:15 PM
Presentation Time: 3:00 PM
Location: San Diego Convention Center, Ballroom 20 C-D
Trial Results
- Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients ≤ 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181
Presenter: Nina D. Wagner-Johnston, MD (Johns Hopkins University)
Oral Abstract 236 in Session 623
Date and Time: Saturday, December 7, 2:00 - 3:30 PM
Presentation Time: 2:15 PM
Location: Marriott Marquis San Diego Marina, Grand Ballroom 11-13 - Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Pre0905 Study in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)
Presenter: Selina M. Luger, MD (University of Pennsylvania)
Oral Abstract 221 in Session 617
Date and Time: Saturday, December 7, 2:00 - 3:30 PM
Presentation Time: 3:00 PM
Location: Manchester Grand Hyatt San Diego, Seaport Ballrooms E-F-G-H
Other New Data from ECOG-ACRIN Trials
PKCδ-Mediated Phosphorylation of CD25 Initiates Feedback Control of Oncogenic Tyrosine Kinases in Acute Lymphoblastic Leukemia
Presenter: Ruifeng Sun, BS (Yale University)
Oral Abstract 632 in Session 614
Date and Time: Sunday, December 8, 4:30 - 6:00 PM
Presentation Time: 4:45 PM
Location: Marriott Marquis San Diego Marina, Grand Ballrooms 5-6- Safety and Efficacy in Pediatric Patients with Relapsed/Refractory Classic Hodgkin Lymphoma Enrolled on an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin (E4412)
Presenter: Christopher J. Forlenza, MD (Memorial Sloan Kettering Cancer Center)
Poster Abstract 4427 in Session 624
Date and Time: Monday, December 9, 2024, 6:00 - 8:00 PM
Location: San Diego Convention Center, Halls G-H
Presenters are available for media interviews under the ASH Meeting Embargo Policy. To schedule an interview, send an email to Diane Dragaud, Director of Communications, at communications@ecog-acrin.org.
About ECOG-ACRIN
The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) is a membership-based scientific organization known for advancing precision medicine and biomarker research through its leadership of major national clinical trials that integrate cutting-edge genomic approaches. Nearly 21,000 member researchers and advocates from approximately 1,400 cancer centers and community hospitals collaborate across ECOG-ACRIN’s nearly 40 scientific committees to design studies spanning the cancer care spectrum, from early detection to management of advanced disease. ECOG-ACRIN is funded primarily by the National Cancer Institute (NCI), part of the National Institutes of Health, through the National Clinical Trials Network (NCTN) and NCI Community Oncology Research Program (NCORP). To learn more, visit www.ecog-acrin.org and follow us on X/Twitter @EAonc, Facebook, LinkedIn, YouTube, and Instagram.
About PrECOG
PrECOG, LLC is a cancer research organization that designs and conducts innovative oncology studies through industry partnerships and research networks. The central focus of PrECOG is to conduct trials that align with the overall scientific mission and research goals of ECOG-ACRIN. To learn more, visit www.precogllc.org and follow us on X/Twitter @PrECOGonc, Facebook, and LinkedIn.